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Abstract: Piribedil is a D2 dopamine agonist, which has been
shown to improve symptoms of Parkinson’s disease (PD) when
combined with L-dopa. The objective of this study was to
compare the efﬁcacy of piribedil monotherapy to placebo in
patients with early PD over a 7-month period. Four hundred
and ﬁve early PD patients were randomized (double-blind) to
piribedil (150–300 mg/day) or placebo. L-dopa open-label sup-
plementation was permitted. Uniﬁed Parkinson Disease Rating
Scale part III (UPDRS III) score as the last observation on
monotherapy over 7 months was the primary outcome measure.
Secondary outcomes were proportion of responders (UPDRS
III improvement  30%), patients remaining on monotherapy
after 7 months, UPDRS III subscores, and UPDRS II. UPDRS
III improved on piribedil (4.9 points) versus a worsening on
placebo (2.6 points; estimated effect  7.26 points; 95% CI 
5.38–9.14; P  0.0001). The proportion of responders was
signiﬁcantly higher for piribedil (42%) than for placebo (14%)
(OR  4.69; 95% CI  2.82–7.80; P  0.001). Piribedil
signiﬁcantly improved several UPDRS III subscores. UPDRS
II improved on piribedil by 1.2 points, while it deteriorated
by 1.5 points on placebo (estimated effect  2.71; 95% CI 
1.8–3.62; P  0.0001). The proportion of patients remaining
on monotherapy after 7 months was greater in the piribedil
group (OR  3.72; 95% CI  2.26–6.11; P  0.001). Safety
was consistent with that reported for other dopamine agonists,
gastrointestinal side effects being the most common (22% of
patients in piribedil group vs. 14% on placebo). Piribedil is
effective and safe as early PD therapy. © 2006 Movement
Disorder Society
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Although L-dopa therapy improves motor symptoms
of patients with Parkinson’s disease (PD), the emergence
of motor ﬂuctuations and dyskinesias poses a major
therapeutic challenge.1–3 The early use of a dopamine
agonist delays or prevents the development of motor
complications4,5 for at least 5 years.
Piribedil [(methylenedioxy-3,4-benzyl)-4 pyperazinyl-
1-2 pyrimidine], a centrally acting nonergoline dopamine
agonist6 with afﬁnity for D2 and D3 receptors7,8 and
signiﬁcant activity on animal models of PD,9 has been
used for many years in the treatment of PD.10 Controlled
studies have demonstrated piribedil efﬁcacy in combina-
tion with L-dopa,11–13 but only one open-label 3-month
study has reported a favorable therapeutic proﬁle of
piribedil monotherapy in de novo patients.14
The REGAIN (Early Treatment of Idiopathic PD With
the Dopaminergic Agonist Trivastal 50 Retard in Mono-
therapy) multicenter randomized double-blind placebo-
controlled study was carried out to conﬁrm the therapeu-
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tic efﬁcacy of piribedil as monotherapy in de novo
patients. We now report the results of the planned
7-month analysis of a 2-year study.
PATIENTS AND METHODS
This multinational multicenter study used a random-
ized double-blind two-group parallel design and was
conducted in agreement with the principles of Good
Clinical Practice and the Declaration of Helsinki. The
protocol was approved by the relevant institutional ethics
committees. All patients freely gave their written in-
formed consent before participation.
Patients
Patients aged 30 to 77 years with a diagnosis of
idiopathic PD (according to Queen Square Brain Bank
for Neurological Disorders criteria)15 at stage 1 to 3 on
the Hoehn and Yahr’s scale16 were eligible. Previous
treatment with dopamine agonists for less than 3 months
and L-dopa for less than 6 weeks was permitted. Dopa-
mine agonists, anticholinergics, selegiline, and amanta-
dine had to be discontinued for at least 1 month (60 days
in case of selegiline) prior to screening.
Ongoing treatments with anxiolytic, hypnotic, and an-
tidepressant drugs were continued unchanged throughout
the trial. Selective serotonin reuptake inhibitors were
authorized if started at least 3 months before and at stable
daily dose. Treatment with nonselective monoamine ox-
idase inhibitors, amineptine, imipramine, and derivates
were the exclusion criteria.
Study Design
Patients underwent a run-in single-blind placebo pe-
riod of 30 days and then were randomized to one of the
two treatment arms, piribedil or placebo. Three main
visits, when a full clinical evaluation was performed,
were scheduled: at day 0 (inclusion visit), after 7 months,
and after 24 months. Double-blind conditions were kept
from randomization up to the end of the 2-year study
(Fig. 1A). The present report focuses on the clinical and
safety assessments performed at baseline, day 28, day 42,
and after 4 and 7 months. All criteria were evaluated
either over the 7-month period under piribedil mono-
therapy condition or until the last visit prior to L-dopa
rescue (last change, LOCF; planned analysis, main study
objective).
The primary efﬁcacy endpoint was the mean change at
endpoint versus baseline of the Uniﬁed Parkinson Dis-
ease Rating Scale part III (UPDRS III) score.17 Second-
ary motor endpoint included the percentage of respond-
ers, deﬁned by a 30% decrease from baseline on the
UPDRS III score.17 Other secondary criteria were UP-
DRS III subscores [tremor at rest (item 20), action or
postural tremor score (item 21), rigidity score (item 22),
bradykinesia score (items 23–27, 31), axial score (items
18, 28–30), and UPDRS II score (activities of daily
living)]. Other exploratory endpoints included the time to
failure (deﬁned as the number of days from day 0 to the
introduction of L-dopa), the percentage of patients on
L-dopa, the L-dopa daily dose, Montgomery and Asberg
Depression Rating Scale (MADRS) scores, Beck De-
pression Inventory total scores, and quality of life of
patients (PDQL) total scores expressed as raw values.
Cognitive evaluations, performed at inclusion and after a
7- and 24-month period, included the Stroop test, the
Wisconsin Card Sorting Test, Verbal ﬂuency, Digit Or-
dering, and Reversed Digit Symbol. Results of these last
evaluations will be presented in a separate paper.
Safety evaluations included blood pressure, heart rate,
and an open-question interview. Adherence was calcu-
lated by a count of unused medication. Standard biolog-
ical analyses were performed at inclusion and after 7
months.
Piribedil was taken as 50 mg tablets, or identical
matching placebo tablets. The starting dose was 50 mg
o.d., which was then increased every week in increments
of 50 mg up to 150 mg t.i.d. by day 21. The daily dose
could be increased thereafter in increments of 50 mg
every 14 days in the event of lack of effect, with three
possible stable dose regimens (150, 200, and 250 mg/
day) up to month 4. During this period, piribedil could be
also downtitrated by steps of 50 mg in the event of
intolerance. After month 4, the investigator was allowed
to increase the medication to a maximal level of 300 mg
per day (Fig. 1B). After day 42, open-label rescue treat-
ment with L-dopa was permitted. Domperidone (up to 60
mg/day) was prescribed to control gastrointestinal symp-
FIG. 1. A: Study design. B: Study treatment.
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toms up to day 42 and could be continued thereafter,
depending on clinical need.
Statistical Analysis and Sample Size Considerations
Randomization procedures were performed via IVRS
(by Clinphone, Nottingham, U.K.). Main analyses were
performed on an intention-to-treat (ITT) basis [all ran-
domized patients who received at least one dose of
treatment and had fully recorded baseline (D0) data].
Piribedil and placebo groups were compared over the
7-month period in true monotherapy conditions by using
an analysis of covariance by group, presence of previous
L-dopa treatment, and country as ﬁxed effects and with
baseline value as a covariate. In case of L-dopa supple-
mentation before M7, the last monotherapy value was
considered for analysis (LOCF).
In planning the trial, it was calculated that a trial with
200 patients per arm would have 88% power to detect a
3-point difference at the 2.5% level one-sided given an
assumed standard deviation of 9.5 points.18 The main
analysis was performed at a 2.5% one-sided level signif-
icance. This one-sided approach was justiﬁed by the
long-term open-label utilization of piribedil as an anti-
parkinson drug and by the positive results of controlled
trials in L-dopa–treated PD patients. All other tests were
performed at a level of 5% (two-sided comparisons). As
there was only one main analysis for the primary end-
point, no adjustments for multiplicity were needed.
The difference between treatments in the percentage
of responders was compared using a logistic regression
with baseline UPDRS III score and country as covariates.
Difference between treatments for time to failure (intro-
duction of L-dopa) was analyzed using a Cox proportion-
al-hazards model with baseline UPDRS III score and
country as covariates. Differences between treatments
for the percentage of patients on L-dopa, as well as the
last prescribed L-dopa daily dose, were compared by
using a Cochran–Mantel–Haenszel (CMH) test. In order
to avoid involuntary biases, two different teams of stat-
isticians were in charge of the short-term (7-month) and
the long-term (24-month) analyses.
RESULTS
Four hundred and ﬁve patients recruited by 52 centers
in seven countries (Argentina, India, France, Mexico,
South Africa, Spain, and Portugal) participated in the
trial. One hundred and ninety-seven patients were ran-
domized in the piribedil group and 204 in the placebo
group (Fig. 2). Treatment groups were matched at inclu-
sion (Table 1).
Efﬁcacy
A total of 179 (88%) of 204 patients in the placebo
group and 157 (80%) of 197 in the piribedil group
completed the 7-month period (Fig. 2). A total of 187
patients in the piribedil group and 199 in the placebo
group were included in the ITT main analysis.
At endpoint, the mean daily dose of piribedil was
240  55 mg/day. UPDRS III score improved by
4.9  9.8 points on piribedil, while the score deterio-
FIG. 2. Disposition of patients.
TABLE 1. Characteristics of the population at baseline
Placebo
(n  204)
Piribedil
(n  197)
Age (yr) 62.3  10.3 62.4 9.5
Male sex 128 (62.7%) 116 (58.9%)
PD duration (yr) 2.0 2.0 2.0  1.8
Hoehn and Yahr 2  0.5 2.1  0.5
Class 1-1.5 58 (28.4) 47 (23.9%)
Class 2-2.5 128 (62.7%) 133 (67.5%)
Class 3 18 (8.8%) 16 (8.1%)
MADRS score 6.5 7.2 7.7  7.2
UPDRS III score 23.1  11.5 25.9 11.7
UPDRS III axial score 2.3  1.6 2.7  1.6
Values are mean  SD or n (%).
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rated by 2.6  8.9 points on placebo (estimated effect 
7.26; 95% CI  5.38–9.14; P  0.0001; Fig. 3). The
number of responders was also greater with piribedil
(42% vs. 14% with placebo, logistic regression; odds
ratio  4.69; 95% CI  2.82–7.80; P  0.001).
When compared to placebo, piribedil signiﬁcantly im-
proved UPDRS II by 1.2  4.6 points from baseline,
while the score deteriorated by 1.5  4.4 points on
placebo (estimated effect  2.71; 95% CI  1.8–3.62;
P 0.0001; Fig. 3). Piribedil also signiﬁcantly improved
all UPDRS III subscores (Table 2).
The rate of patients taking L-dopa was signiﬁcantly
higher (odds ratio  3.72) in the placebo group than in
patients receiving piribedil (P  0.001). At M7, 17% of
piribedil-treated patients received L-dopa rescue treat-
ment compared with 40% in the placebo arm (P 
0.0001; Fig. 4). In the patients who needed L-dopa sup-
plementation, the mean last prescribed dose was 346 
148 mg/day in the placebo group (n  80) and 344 
141 mg/day in the piribedil group (n  31). Overall in
the study population, a signiﬁcant difference in the last
prescribed L-dopa daily dose was demonstrated in favor
of piribedil (estimated effect  81.39  16.72; P 
0.0001).
Safety and Tolerability
Sixty-nine percent of the patients in the piribedil group
and 57% in the placebo group reported at least one
emergent adverse event, but medication was stopped in
only 4.7% of patients (2.0% in placebo and 7.5% in the
piribedil group) because of adverse events.
The most common treatment emergent adverse events
were gastrointestinal symptoms (61 [31%] of 200 pa-
tients on piribedil; 29 [14%] of 205 patients on placebo),
psychiatric disorders (46 [23%] of 200 patients on piribe-
dil; 36 [18%] of 205 patients on placebo), and body as a
whole general disorders (41 [21%] of 200 patients on
piribedil; 28 [14%] of 205 patients on placebo). The most
frequently occurring emergent adverse events are re-
ported in Table 3. After 7 months, 42 patients (10.4%)
experienced at least one serious adverse event: 10 pa-
tients (4.9%) in placebo group and 17 patients (8.5%) in
piribedil group.
Adverse events led to discontinuation of the study
medication in 15 piribedil- and 5 placebo-treated pa-
tients. Gastrointestinal symptoms (5 patients) and psy-
chiatric symptoms, including hallucinations (4 patients;
1.0%), were the most frequent reason for discontinuation
in the active treatment group, whereas in the placebo
group, the most common reason for adverse event-re-
lated withdrawal was the aggravation of speciﬁc motor
symptoms (2 patients).
Over 7 months in the safety set (n 405), irrespective
of the introduction of L-dopa, vital signs mean values
FIG. 3. UPDRS III and II changes between baseline and endpoint on
piribedil or placebo monotherapy (month 7 or last monotherapy value
before L-dopa supplementation being carried forward).
TABLE 2. Effects of piribedil on the main subscores of UPDRS III at 7 months
Placebo
(n  199)
Piribedil
(n  187)
Estimated
effect P
Tremor at rest (item 20a–20e) 0.4 (2.2) 1 (2.2) 1.33  0.21  0.0001
Action or postural tremor (item 21a–21b) 0.1 (1.3) 0.2 (1.3) 0.31 0.12  0.01
Rigidity (item 22a–22e) 0.3 (2.7) 0.7 (2.6) 0.96 0.26  0.0005
Bradykinesia (items 23a, 23b, 24a, 24b, 25a, 25b, 26a, 26b, 27, 31) 1.4 (4.4) 2.4 (5) 3.57  0.48  0.0001
Axial score (items 18, 28-30) 0.3 (1.2) 0.3 (1.3) 0.47  0.12  0.0005
Last change versus baseline in monotherapy condition.
FIG. 4. Time to introduction of L-dopa.
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remained stable from baseline to the last observation in
both treatment arms.
DISCUSSION
The dopamine agonist piribedil has been used for
many years for the treatment of PD in several countries.
However, there is a lack of data regarding the efﬁcacy of
piribedil in monotherapy in de novo patients based on
randomized double-blind placebo-controlled results. The
present results demonstrate that piribedil monotherapy is
more efﬁcacious than placebo over 7 months in de novo
patients, as determined by changes in UPDRS II and III
and need for L-dopa supplementation.
Piribedil (150–300 mg/day) as monotherapy de-
creased the UPDRS III score with a signiﬁcant treatment
effect of 7.26 points versus placebo (P  0.0001). This
effect size may be compared with the results reported in
comparable populations and comparable trial design with
other dopamine agonists such as ropinirole (effect size of
about 5 points),19 pramipexole (effect size of about 6
points),20 pergolide (effect size of about 5 points),21 or
rotigotine (effect size of about 4 points).22 The lack of
head-to-head comparison prevents, however, any deﬁnite
conclusions regarding relative efﬁcacy across trials and
across agonists. The piribedil effect size observed in the
REGAIN study was also greater than the one reported
with MAO-B inhibitors such as selegiline or rasagiline
(effect size of 2–3 points.23,24 However, the same cau-
tiousness should apply before drawing any conclusion in
term of relative efﬁcacy.
While it is a frequent empirical observation that
piribedil is highly effective on tremor, the present study
also demonstrated global efﬁcacy on all motor symp-
toms, including rigidity, bradykinesia, and axial symp-
toms. The relationship between axial symptoms and do-
paminergic or nondopaminergic mechanisms remains
controversial.25,26 Therefore, the respective contribution
of the adrenergic versus the dopaminergic activities of
piribedil to its actions on axial symptoms remains uncer-
tain and requires further clariﬁcation.
Piribedil is currently used at a dose of 150 to 250
mg/day in the countries where it is marketed. Uptitrating
piribedil to 300 mg/day was permitted in the REGAIN
trial in order to maintain monotherapy as long as possi-
ble. Thus, the mean daily dose at the last visit was 244
mg/day. The aim of this strategy was to try to reduce the
risk of dyskinesia by delaying L-dopa rescue. The impact
of this strategy on the incidence of dyskinesias will be
assessed in the 2-year analysis, but the present data
demonstrate that the early use of such a dose of piribedil
is a feasible option to delay the introduction of L-dopa
since the number of patients needing L-dopa rescue was
greater for the placebo group (RR  3.02; P  0.0001).
The present study also showed that piribedil, admin-
istered over 7 months up to a dose of 300 mg/day, was
well tolerated in patients with early PD aged 77 years or
less. Of the 197 patients who received piribedil, only
7.5% withdrew because of adverse events. The adverse
events reported (i.e., in more than 5% of treated patients)
with piribedil are typical of the safety proﬁle of an active
dopaminergic drug and comparable to other dopamine
agonists.18,27 Piribedil, however, has not so far been
reported to be associated with ﬁbrotic reactions as seen
with ergoline agonists.28
APPENDIX
The following members of the Parkinson REGAIN Study Group
participated in this study and were authors of this report.
Steering Committee
Clinical Investigation Center, INSERM U455 and University Hos-
pital of Toulouse, Toulouse, France: Olivier Rascol; Instituto de Cie¨n-
sas da Sau`de, UCP of Lisbon, Lisbon, Portugal: Alexandre Castro
Caldas; INSERM U289/Hoˆpital Pitie´-Salpeˆtrie`re, Paris, France: Bruno
Dubois; Department of Statistics, University of Glasgow, Glasgow,
United Kingdom: Stephen Senn; University College London/RETA
LILA, Weston Institute of Neurological Studies, London, United King-
dom: Andrew J. Lees.
Participating Investigators and Coordinators
Argentina: Oscar Gershanik, Jose´ Antonio Bueri, Ruben Femminini,
Rolando Giannaula, Marcelo Merello, Federico Michelli, Gustavo An-
gel Saredo, Eduardo Galli, Diana Simonetti, Santiago Palacio, Guill-
ermo Zeppa, Hector Zezza.
France: Olivier Blin, Anne Marie Bonnet, Jean Louis Montastruc,
Christine Tranchant, Emmanuel Ellie, Guillaume Ballan, Franc¸ois
Viallet.
India: Madhuri Behari, Mohit Bhatt, Rupam Borgohain, Mena
Gupta, Uday Muthane, Arun Shah, Geeta Khwaja, Rangasetty
Srinivasa.
Mexico: Enrique Otero, Javier Jimenez Gil, Lourdes Leon Flores,
Hector Ramon Martinez, IIldefonso Rodriguez Leyva.
TABLE 3. Emergent adverse events occurring
in  5% of patients
Adverse event
Placebo
(n  205)
Piribedil
(n  200)
n % n %
Nausea 8 3.9 24 12.0
Hypertension 9 4.4 19 9.5
Dizziness 9 4.4 15 7.5
Anxiety 9 4.4 13 6.5
Hypotension postural 8 3.9 13 6.5
Insomnia 6 2.9 13 6.5
Constipation 6 2.9 13 6.5
Depression 12 5.9 7 3.5
Somnolence 6 2.9 12 6.0
Edema peripheral 7 3.4 10 5.0
Abdominal pain 4 2.0 12 6.0
Safety set (n  405).
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Portugal: Joaquim Ferreira, Luis Cunha, Jose´ Alves Grillo Gon-
c¸alvez, Antonio Bastos Lima.
Spain: Miguel Aguilar, Jose´ Catalan, Matilde Calopa, Jose´ Manuel
Fernandez Carril, Luis Maria Iriarte Garcia, Exuperio Diez Tejedor,
Jose´ Balseiro Gomez, Carlos Oliveras, Gurutz Linazasoro, Pilar La-
torre, Arancha Gorospe, Jacinto Duarte, Lydia Vela Desojo, Eduardo
Tolosa Sarro.
South Africa: Bryan Kies, James Temlett, John Gardiner, Werner M.
Guldenpfennig, Joahannes Alberto Smuts, Willem S. Van Niekerk,
Franc¸ois Verster, G. Modi.
Sponsor
Institut de Recherches Internationales Servier, Courbevoie, France:
Susanna Del Signore (project director), Nadia Bodjarian (study man-
ager), Karen Fanouille`re (biostatistician).
Third Parties
Contract research organization (monitoring): Quintiles France, Le-
vallois-Perret, France; IVRS, Clinphone, Nottingham, United
Kingdom.
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